Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Propranolol is a drug that is classified as a beta-blocker. Beta-blockers affect the heart and circulation. Beta-blockers, like propranolol, may help to counteract effects of certain stress hormones produce

Trial Details

NCT ID

NCT05741164

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Biopsy
Biospecimen Collection
Computed Tomography
Pembrolizumab
Propranolol
Questionnaire Administration

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

Age \>= 18 years of age
Have pathologically confirmed diagnosis of unresectable or metastatic triple negative breast cancer (TNBC) with no curative treatment options
No chemotherapy, radiotherapy, or major surgery within 4 weeks of protocol treatment
Checkpoint inhibitor refractory patients (i.e., no longer responding to chemotherapy and checkpoint inhibitor) who have disease progression on prio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →